Jens Tijtgat

5PUBLICATIONS
12CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Radiation therapyChemotherapyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jan 11, 2024
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma.

Jens Tijtgat, Xenia Geeraerts, Anais Boisson

|May 13, 2023
Low-Dose Bevacizumab for the Treatment of Focal Radiation Necrosis of the Brain (fRNB): A Single-Center Case Series.

Jens Tijtgat, Evan Calliauw, Iris Dirven

|Feb 15, 2022
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.

Julia Katharina Schwarze, Soizic Garaud, Yanina J L Jansen

|Apr 30, 2021
A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRAS Mutant Melanoma (TraMel-WT).

Gil Awada, Julia Katharina Schwarze, Jens Tijtgat

|Jan 09, 2021
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab.

Gil Awada, Yanina Jansen, Julia Katharina Schwarze

Pageof 1

Frequent Collaborators

5 joint publications

Bart Neyns

4 joint publications

Julia Katharina Schwarze

3 joint publications

Gil Awada

1 joint publications

Yanina Jansen